The cobas® c 703 and cobas® ISE neo analytical units, deliver higher testing capacity and increased automation helping to improve laboratory workflows and advance patient care. The new cobas c 703 ...
First diagnostic solution at the point of care to serve as a digital platform connecting developers of digital health software and applications to healthcare professionals Basel, 12 January 2022 - ...
Roche’s new cloud-based platform connects patient test results, medical records and third-party applications, allowing professionals to monitor patients’ health, adjust treatment protocols, and make ...
INDIANAPOLIS, Oct. 29 /PRNewswire/ -- Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today the U.S. introduction of the cobas e 602 analyzer, the latest addition to the cobas® 8000 modular analyzer ...
PLEASANTON, Calif., March 30, 2012 /PRNewswire/ -- Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today the FDA approval of a new pre-analytical instrument that provides an integrated primary tube ...
Infectious diseases, such as those infections transmitted via respiratory, sexually and transplant, are becoming increasingly difficult to manage and represent an ever-growing medical need for ...
Roche has announced the commercial availability in countries that accept the CE mark1 of the cobas® EGFR Mutation Test v2, the first oncology assay from Roche that utilises either plasma or tumour ...
Roche announced the launch of its new analytical units, cobas c 703 and cobas ISE neo, for the cobas pro integrated solutions, in countries accepting the CE mark. The cobas pro integrated solutions is ...
Handheld blood glucose management device designed around the specific needs of healthcare professionals working in a range of care settings First diagnostic solution at the point of care to serve as a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results